NASDAQ:VIE Viela Bio (VIE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$53.01▼$53.0150-Day Range$52.92▼$53.2052-Week Range$25.02▼$65.00VolumeN/AAverage Volume1.07 million shsMarket Capitalization$2.91 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Viela Bio alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Viela Bio Stock (NASDAQ:VIE)Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.Read More Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. VIE Stock News HeadlinesAugust 19, 2024 | finance.yahoo.comFactor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsightAugust 16, 2024 | bizjournals.com2024 Fire Awards: Meet this year's Ablaze honoreesSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... April 16, 2024 | finance.yahoo.comFcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsightJanuary 29, 2024 | benzinga.comArriVent Wows Investors With Promising China-Developed Lung Cancer TreatmentJanuary 27, 2024 | bizjournals.comArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024January 9, 2024 | seekingalpha.comArriVent Biopharma Seeks $100 Million IPO For Lung Cancer DrugJanuary 5, 2024 | marketwatch.comArriVent BioPharma Files For IPOSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... December 6, 2023 | finance.yahoo.comMyasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%November 17, 2023 | benzinga.comGlobal CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key PlayersNovember 9, 2023 | uk.finance.yahoo.comGlobal CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of TherapiesNovember 3, 2023 | finance.yahoo.comGlobal CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in ImmunotherapyOctober 25, 2023 | bizjournals.comAmgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for nowOctober 23, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerSeptember 20, 2023 | usatoday.comInside 'Elon Musk': Wild details from revealing Walter Isaacson biographyJuly 26, 2023 | nypost.comI’m an AI influencer: Followers crave my sexy snaps — but I don’t existMay 8, 2023 | marketwatch.com2023 Cutaneous Lupus Erythematosus (CLE) Treatment Market: Latest Technology Innovations and Comprehensive Growth Insights by 2031See More Headlines Receive VIE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2021Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:VIE CUSIPN/A CIKN/A Webwww.vielabio.com Phone240 558 0038FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.97% Return on Assets-31.49% Debt Debt-to-Equity RatioN/A Current Ratio19.51 Quick Ratio19.49 Sales & Book Value Annual Sales$50 million Price / Sales58.26 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book7.42Miscellaneous Outstanding Shares54,950,000Free FloatN/AMarket Cap$2.91 billion OptionableNot Optionable Beta0.43 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Zhengbin Yao (Age 55)Chairman, Pres & CEO Comp: $846.75kMr. Mitchell Chan (Age 40)Chief Financial Officer Comp: $420.34kDr. Jörn Drappa M.D. (Age 56)Ph.D., Chief Medical Officer and Head of R&D Comp: $637.39kMr. James Paul Kastenmayer J.D. (Age 49)Ph.D., Gen. Counsel & Company Sec. Ms. Kate SurdezSr. VP & Head of HRMs. Rachel EttingerSr. Director & Head of ResearchMr. Bill ReesSr. Director & Head of Translational ScienceMr. Ted PhillipsVP & Head of Clinical OperationsMr. Dewei SheSr. Director and Head of Biostatistics, Data Management, & ProgrammingMr. Lee LevinSr. Director & Head of QualityMore ExecutivesKey CompetitorsMyovant SciencesNYSE:MYOVKura OncologyNASDAQ:KURAZymeworksNYSE:ZYMEIronwood PharmaceuticalsNASDAQ:IRWDIGM BiosciencesNASDAQ:IGMSView All Competitors VIE Stock Analysis - Frequently Asked Questions How were Viela Bio's earnings last quarter? Viela Bio, Inc. (NASDAQ:VIE) released its quarterly earnings results on Sunday, February, 28th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.10. The firm had revenue of $9.34 million for the quarter, compared to analysts' expectations of $5.10 million. When did Viela Bio IPO? Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Guggenheim Securities was co-manager. This page (NASDAQ:VIE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viela Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viela Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.